ADXS Advaxis Inc.

0.4
-0.01  -2%
Previous Close 0.41
Open 0.41
Price To Book 0.18
Market Cap 7,556,079
Shares 18,670,815
Volume 922,049
Short Ratio
Av. Daily Volume 568,921

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Enrollment to be terminated - noted November 2, 2018.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Phase 1 monotherapy, overall survival was 8.5 months, combo with Keytruda 23 months.
ADXS-PSA and Keytruda - KEYNOTE-046
Castrate-resistant prostate cancer
Phase 3 trial closed - noted June 27, 2019.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
ADXS-HER2
HER2-driven malignancies - cancer
Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
Axalimogene filolisbac
Anal cancer (FAWCETT)
Phase 1 safety and immunogenicity data presented at AACR March 2019
ADXS-NEO
Non-small cell lung cancer (NSCLC)
Phase 1/2 preliminary data due 2H 2019.
ADXS-HOT 503
Non-small cell lung cancer (NSCLC)

Latest News

  1. BriaCell Appoints Richard J. Berman to Board of Directors
  2. Advaxis, Inc. Announces Closing of $17 Million Public Offering and Exercise in Full of the Underwriters' Over-Allotment Option
  3. The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index
  4. Advaxis, Inc. Announces Pricing of $16 Million Public Offering
  5. New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies
  6. Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study
  7. Edited Transcript of ADXS earnings conference call or presentation 11-Jun-19 3:00pm GMT
  8. Advaxis, Inc. to Host Earnings Call
  9. Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update
  10. Advaxis to Host Business Update Conference Call on June 11, 2019
  11. What Kind Of Investor Owns Most Of Advaxis, Inc. (NASDAQ:ADXS)?
  12. Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug
  13. FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac
  14. Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference
  15. Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer
  16. Advaxis to Participate in Five Upcoming Industry Conferences
  17. Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know
  18. QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
  19. Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session
  20. Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?